Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKD-331
- Development stage
- Phase 1
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CKD-331 is an orally administered small molecule drug under development by Chong Kun Dang Pharmaceutical for the treatment of dyslipidemia (including hypercholesterolemia), hypertension, and diabetic nephropathy. Its primary indications are metabolic and cardiovascular diseases such as primary hypercholesterolemia and hypertension. The drug has reached Phase 3 clinical trials for primary hypercholesterolemia and is also being investigated in earlier phases for other related conditions. The precise mechanism of action has not been publicly disclosed as of the latest updates, but it targets metabolic pathways relevant to lipid regulation and possibly kidney protection in diabetes.
Beyond the preview
Go deeper on CKD-331.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CKD-331.